Avexa Limited Presents Data from Apricitabine and Antibacterial Programs at two International Conferences

MELBOURNE, Australia--(BUSINESS WIRE)--Australian biotechnology company Avexa (ASX:AVX) today announced the presentation of 48 week data from its apricitabine program at the Ninth International Congress on Drug Therapy in HIV Infection held in Glasgow, UK, 9-13 November 2008. The previous week the company presented data on its antibacterial program at the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) / Infectious Diseases Society of America (IDSA) 46th annual meeting, held 25-28 October 2008, in Washington, D.C.